Which states have published rules about BPC-157?
As of 2026-11-20, 3 states have published sentences naming BPC-157: Alabama, Kentucky, Ohio. 5 more (Maryland, Mississippi, Missouri, South Carolina, Utah) have rules about a whole class of drugs that BPC-157 falls into, without naming it. We read the boards of 44 states every night. In 6 more we read statutes and rules only, so silence there tells you less.
The states that have published
Alabama
Coverage is limited to the six peptide identities and their specified administration routes: Peptide Covered form Covered route or dosage form BPC-157 Acetate Subcutaneous, intramuscular, oral, and topical TB-500 Acetate Subcutaneous or intramuscular injection Epitalon Acetate Subcutaneous or intramuscular injection, dispensed in intermittent courses Semax Free base Intranasal KPV Acetate Topical and oral MOTS-c Acetate Subcutaneous or intramuscular injection *Acetate refers to a common salt form of the peptide.
AL medical board: Hhs enforcement discretion policy regarding 503a compounding using certain peptide bulk drug substances. Read it on the source · last read 2026-11-20 The same sentence is also on AL medical board: FAQs HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.
Background, not this state's own rule
The policy covers six substances: BPC-157, epitalon, KPV, MOTS-c, Semax, and TB-500.
AL medical board: Hhs enforcement discretion policy regarding 503a compounding using certain peptide bulk drug substances. Read it on the source · last read 2026-11-20 The same sentence is also on AL medical board: FAQs HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.
Kentucky
New rule found, see quote
Do not compound any preparation for human use from BPC-157, TB-500, Epitalon, Semax, KPV or MOTS- c, whether for an individual patient, office use or any other purpose.
KY pharmacy board: Frankfort, Ky. (November 19, 2026) Compliance Alert: Compounding With Peptide Bulk Drug Substances Under the HHS Enforcement Discretion Policy. Read it on the source · last read 2026-11-20
The six substances are BPC-157, TB-500 (thymosin beta-4 fragment), Epitalon, Semax, KPV and MOTS-c.
KY pharmacy board: Frankfort, Ky. (November 19, 2026) Compliance Alert: Compounding With Peptide Bulk Drug Substances Under the HHS Enforcement Discretion Policy. Read it on the source · last read 2026-11-20
OhioEverything Ohio published about peptides
Additionally, peptides such as BPC-157 and other bulk drug substances in category 2 and 3 (see FDA guidance ) cannot be compounded because it violates federal and state law.
OH pharmacy board: Ten Common Prescriber Clinic and Medical Spa Violations. Read it on the source · last read 2026-11-20
Rules that reach BPC-157 without naming it
These are about a whole class of drugs, such as any drug a practitioner prescribes. Each says which class beside it.
Maryland
A telehealth practitioner may not treat a patient or prescribe medication based solely on a static online questionnaire.
MD COMAR 10.32.05, telehealth (Division of State Documents bulk XML). This is a rule about any drug a practitioner prescribes. BPC-157 is one, so it applies. The rule does not name BPC-157. Read it on the source · last read 2026-11-10
Mississippi
New rule found, see quote
Under no circumstances is it permissible for a healthcare provider to compound, administer, or dispense a non- FDA approved or research-grade peptide to a patient.
MS pharmacy board: Joint Statement on the Prescribing of Non-FDA Approved (Research-Grade) Peptides. This is a rule about a peptide sold as research-grade or not eligible under FDA's rules. BPC-157 is one, so it applies. The rule does not name BPC-157. Read it on the source · last read 2026-11-20
Missouri
No health care provider, as defined in section 376.1350 , shall prescribe any drug, controlled substance, or other treatment to a patient based solely on an evaluation through telemedicine; except that, a physician or such physician's on-call designee, or an advanced practice registered nurse, a physician assistant, or an assistant physician in a collaborative practice arrangement with such physician, may prescribe any drug, controlled substance, or other treatment that is within his or her scope of practice to a patient based solely on a telemedicine evaluation if a previously established and ongoing physician-patient relationship exists between such physician and the patient being treated.
MO Revised Statutes 334.108. This is a rule about any drug a practitioner prescribes. BPC-157 is one, so it applies. The rule does not name BPC-157. Read it on the source · last read 2026-11-10
South Carolina
New rule found, see quote
All drugs administered or dispensed to a patient must be prescription/pharmaceutical quality; therefore, under no circumstances is it permissible for a physician to compound, administer, prescribe, or dispense research-grade or FDA-ineligible peptides to a patient.
SC medical board: BME Notice re Peptides. This is a rule about a peptide sold as research-grade or not eligible under FDA's rules. BPC-157 is one, so it applies. The rule does not name BPC-157. Read it on the source · last read 2026-11-20
Utah
New rule found, see quote
DOPL will apply enforcement discretion only when each condition listed in the HHS interim policy is met.
UT Division of Professional Licensing: Peptide Enforcement Discretion Policy (30 October 2026). This is a rule about one of the six peptides in HHS's 503A enforcement discretion policy of 30 October 2026. BPC-157 is one, so it applies. The rule does not name BPC-157. Read it on the source · last read 2026-11-20
Every state
Nothing on record means we have found no sentence naming BPC-157 in what that state publishes. It is not permission.
| State | What its own sources say about BPC-157 | What we read |
|---|---|---|
| Alabama | 2 sentences naming it, quoted above | Board and laws, 11 of 11 sources answered |
| Alaska | Nothing on record | Laws only: we do not read this board's own guidance. 2 of 5 sources answered |
| Arizona | Nothing on record | Board and laws, 4 of 6 sources answered |
| Arkansas | Nothing on record | Board and laws, 4 of 4 sources answered |
| California | Nothing on record | Board and laws, 4 of 4 sources answered |
| Colorado | Nothing on record | Laws only: we do not read this board's own guidance. 1 of 5 sources answered |
| Connecticut | Nothing on record | Board and laws, 4 of 4 sources answered |
| Delaware | Nothing on record | Board and laws, 4 of 4 sources answered |
| Florida | Nothing on record | Board and laws, 6 of 6 sources answered |
| Georgia | Nothing on record | Board and laws, 3 of 3 sources answered |
| Hawaii | Nothing on record | Board and laws, 5 of 5 sources answered |
| Idaho | Nothing on record | Board and laws, 4 of 4 sources answered |
| Illinois | Nothing on record | Board and laws, 1 of 1 source answered |
| Indiana | Nothing on record | Board and laws, 2 of 2 sources answered |
| Iowa | Nothing on record | Board and laws, 3 of 3 sources answered |
| Kansas | Nothing on record | Board and laws, 3 of 5 sources answered |
| Kentucky | 2 sentences naming it, quoted above | Board and laws, 5 of 5 sources answered |
| Louisiana | Nothing on record | Board and laws, 4 of 4 sources answered |
| Maine | Nothing on record | Board and laws, 4 of 6 sources answered |
| Maryland | Nothing naming it. A rule about a class it falls into, quoted above | Board and laws, 4 of 4 sources answered |
| Massachusetts | Nothing on record | Laws only: we do not read this board's own guidance. 5 of 7 sources answered |
| Michigan | Nothing on record | Board and laws, 4 of 6 sources answered |
| Minnesota | Nothing on record | Board and laws, 11 of 11 sources answered |
| Mississippi | Nothing naming it. A rule about a class it falls into, quoted above | Board and laws, 6 of 7 sources answered |
| Missouri | Nothing naming it. A rule about a class it falls into, quoted above | Board and laws, 12 of 12 sources answered |
| Montana | Nothing on record | Board and laws, 2 of 2 sources answered |
| Nebraska | Nothing on record | Board and laws, 2 of 2 sources answered |
| Nevada | Nothing on record | Board and laws, 3 of 3 sources answered |
| New Hampshire | Nothing on record | Board and laws, 5 of 7 sources answered |
| New Jersey | Nothing on record | Laws only: we do not read this board's own guidance. 3 of 7 sources answered |
| New Mexico | Nothing on record | Board and laws, 5 of 5 sources answered |
| New York | Nothing on record | Board and laws, 2 of 2 sources answered |
| North Carolina | Nothing on record | Board and laws, 3 of 3 sources answered |
| North Dakota | Nothing on record | Board and laws, 5 of 5 sources answered |
| Ohio | One sentence naming it, quoted above | Board and laws, 4 of 4 sources answered |
| Oklahoma | Nothing on record | Board and laws, 1 of 1 source answered |
| Oregon | Nothing on record | Board and laws, 3 of 3 sources answered |
| Pennsylvania | Nothing on record | Board and laws, 2 of 2 sources answered |
| Rhode Island | Nothing on record | Laws only: we do not read this board's own guidance. 4 of 5 sources answered |
| South Carolina | Nothing naming it. A rule about a class it falls into, quoted above | Board and laws, 4 of 4 sources answered |
| South Dakota | Nothing on record | Board and laws, 10 of 11 sources answered |
| Tennessee | Nothing on record | Board and laws, 7 of 8 sources answered |
| Texas | Nothing on record | Board and laws, 3 of 3 sources answered |
| Utah | Nothing naming it. A rule about a class it falls into, quoted above | Board and laws, 6 of 6 sources answered |
| Vermont | Nothing on record | Board and laws, 5 of 5 sources answered |
| Virginia | Nothing on record | Laws only: we do not read this board's own guidance. 6 of 6 sources answered |
| Washington | Nothing on record | Board and laws, 4 of 4 sources answered |
| West Virginia | Nothing on record | Board and laws, 3 of 3 sources answered |
| Wisconsin | Nothing on record | Board and laws, 5 of 5 sources answered |
| Wyoming | Nothing on record | Board and laws, 6 of 6 sources answered |
The federal position, which applies in every state
Federal sentences are shown here once, separately from what each state published.
BPC-157 Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization.
FDA, same page, table headed "Bulk drug substances nominated but withdrawn": previously in category 2, withdrawn by the nominators. Read it on the source
Until a peptide bulk drug substance is addressed in a final rule as being included or not included on the 503A bulks list, HHS does not intend to take action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a peptide bulk drug substance that is not a component of an FDA-approved drug product, the subject of an applicable USP or NF monograph, or on the 503A bulks list codified at 21 CFR 216.23(a), when all of the following circumstances are present:
The 10 conditions, as the policy writes them
- 503A Interim Access List. The peptide bulk drug substance appears in Appendix A to this policy.
- Identity of the Peptide Bulk Drug Substance. The peptide bulk drug substance has the identity and limitations in route of administration described in Appendix B. The identity includes but is not limited to amino acid sequence, chemical structure, molecular weight, and molecular formula.
- Characterization. The bulk drug substance is from a facility registered under section 510 (21 U.S.C. § 360) and characterized and identified in a valid certificate of analysis (COA) that includes test results consistent with existing guidance-based criteria described by FDA (see Appendix B). This helps provide assurance that what a compounder receives from a supplier is what it claims to be and has been tested for identity, purity, potency, and the absence of harmful contaminants such as endotoxins, heavy metals, microbial contamination, and impurities.
- The original manufacturer of the bulk drug substance (not a subsequent packer, repacker, labeler, or distributor) is registered with FDA under section 510, is in compliance with CGMP and other FD&C requirements and the physical location of the facility is listed on the COA provided to the 503A compounder. If the peptide bulk drug substance is obtained through an FDA-registered repacker, relabeler, or reseller, that entity has itself performed and documented appropriate vendor validation of the bulk drug substance manufacturer and validation of the manufacturer's COA.
- Report products compounded, serious adverse events, and product quality issues to FDA and to the States where the products are compounded and sent (if different). Compounders report serious adverse events associated with the use of the compounded drug product in humans (regardless of whether or not considered drug related) and product quality issues (e.g., information concerning any bacteriological contamination, or any significant chemical, physical, or other change in the distributed drug product, or any failure of a product to meet applicable specifications) to FDA's MedWatch Safety Information and Adverse Event Reporting Program. This provides an opportunity for FDA and States to act on emerging risks. In addition, the procedure for reporting adverse events and issues with the identity, strength, purity, and/or quality of the product should be detailed on the product labeling provided to the patient. Product reporting for the compounder includes the following
- a. Active ingredient and strength of active ingredient per unit;
- b. Original manufacturer of the active ingredient, including unique facility identifier for the manufacturing facility; and
- c. Dosage form and route of administration.
- Product labeling. Product labeling that includes the following statement: "This is a compounded drug product. Not for resale."
- The compounded drug product contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A. It will be easier to attribute adverse events or clinical outcomes to a specific substance, which is essential for meaningful safety surveillance and signal detection, if compounded peptide products include a single API.
- Route of administration. Achieving adequate oral bioavailability of peptides is inherently difficult and complex. Therefore, if a peptide is compounded in an oral dosage form, the compounder is expected to maintain documentation confirming that the specific formulation provided to a patient achieves an adequate level of oral bioavailability in humans.
- Drug delivery device. The only drug delivery device co-packaged or containing the compounded drug is an FDA 510(k)-cleared syringe. More complex drug delivery devices introduce additional patient risk.
- The drug product is compounded in compliance with all other applicable requirements of the FD&C Act including that the drug product not be compounded under insanitary conditions (21 U.S.C. § 351(a)(2)(A)) and section 503A's (21 U.S.C. 353a) patient specific prescription requirement.
Based on the identified updated information, enforcement discretion for BPC-157 acetate is appropriate for subcutaneous, intramuscular, oral, and topical dosage forms that are compounded from API accompanied by a certificate of analysis (CoA) meeting the conditions of this policy.
HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Read it on hhs.gov · copy obtained 2026-11-05
We report what each source says, in its own words. We do not give legal advice. Nothing on record is not permission.
Every state's sources were last read on 2026-11-20. This page is rebuilt from them each time it loads.